Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Brest – page 48

591 clinical trials in Brest, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Brest at a glance
591
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

591 trials in Brest

Open in trial search

Autoimmune haemolytic anaemia+1

Not recruiting

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Incyte Corp.

Dermatitis atopic

Not recruiting

Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clobetasol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Pulmonary arterial hypertension

Not recruiting

Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Neoplasm

Not recruiting

Study on the Safety and Effectiveness of TNG462 for Patients with Advanced or Metastatic Solid Tumors with MTAP Deletion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Midazolam
  • Sponsor:Tango Therapeutics Inc.

Ovarian epithelial cancer

Not recruiting

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Bile duct cancer

Not recruiting

Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Food allergy

Not recruiting

Study on the Effectiveness and Safety of DBV712 for Peanut Allergy in Children Aged 4-7

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Water For Injection
  • Sponsor:Dbv Technologies

Breast cancer metastatic

Not recruiting

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Unicancer

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Brest

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck squamous cell carcinoma, exploring innovative treatments combining radiotherapy with targeted therapies. Studies also examine new approaches for esophageal cancer and pancreatic adenocarcinoma.

  • Advanced Cancer Therapies
  • Combination Treatments
  • Targeted Therapeutics

Multiple trials are investigating novel drug combinations and immunotherapy approaches for various cancer types.

02 Autoimmune Conditions

Comprehensive research into Sjögren's syndrome treatment options, including innovative biological therapies and histopathological studies. Additional focus on rheumatoid arthritis and novel therapeutic approaches.

  • Biological Treatments
  • Disease Mechanisms
  • Treatment Response

Studies aim to understand disease mechanisms and evaluate new therapeutic options for autoimmune disorders.

03 Cardiovascular and Respiratory Studies

Investigation of treatments for pulmonary arterial hypertension and heart failure prevention. Research includes innovative drug combinations and preventive approaches for cardiovascular conditions.

  • Heart Failure Prevention
  • Hypertension Management
  • Asthma Control

Focus on developing effective treatments for chronic cardiovascular and respiratory conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.